Benitec Biopharma Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines. Its core technology is the Silence and Replace platform, a DNA-directed RNA interference (ddRNAi) approach that combines RNA interference with gene therapy. This platform aims to simultaneously silence disease-causing genes and deliver wildtype replacement genes after a single administration of the therapeutic construct. The company's lead product candidate is BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy (OPMD) related dysphagia. Benitec is headquartered in Hayward, California, and operates in the United States.

Benitec Biopharma Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol BNTC. The company trades in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange. The NasdaqCM is a market tier of the Nasdaq stock exchange that lists smaller-capitalization companies, providing them with access to public capital markets. Investors can buy and sell BNTC shares during regular trading hours on the NasdaqCM, and the stock is quoted in USD.

Benitec Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and genetic engineering to develop therapies. In particular, Benitec is a clinical-stage biotech firm, meaning it has not yet commercialized any products but is actively conducting clinical trials. Its work centers on genetic medicines, leveraging its proprietary Silence and Replace platform to create treatments for genetic disorders. The biotechnology industry is known for high research and development costs, long development timelines, and significant regulatory oversight, which are all relevant to Benitec's operations.

Benitec Biopharma Inc. is headquartered in Hayward, California, United States. The company primarily serves the US market, as indicated by its listing on a US exchange and its focus on developing therapies for conditions like oculopharyngeal muscular dystrophy (OPMD), which affects patients globally but has a significant presence in North America and Europe. While Benitec is a US-based company, its clinical-stage programs and potential future products could target international markets. However, based on the available data, the company's operations and headquarters are firmly in the United States, and it operates under US regulatory frameworks such as the FDA.